|  | 100% positive assessments 1 | 0–49% positive assessments 2 | ||||||
---|---|---|---|---|---|---|---|---|---|
 |  | Prev.(%) | PR | Adj. PR | 95% CI | Prev.(%) | PR | Adj. PR | 95% CI |
Gender | |||||||||
(N = 25533) | Female | 63.8 | 1 | 1 | Â | 14.9 | 1 | 1 | Â |
 | Male | 65.1 | 1.02 | 0.98 | 0.96 – 1.00 | 13.0 | 0.87 | 0.93 | 0.86 – 1.00 |
Age (years) | |||||||||
(N = 25533) | 18–24 | 52.3 | 1 | 1 |  | 16.4 | 1 | 1 |  |
 | 25–29 | 54.3 | 1.04 | 1.03 | 0.96 – 1.10 | 16.6 | 1.03 | 1.03 | 0.87 – 1.22 |
 | 30–34 | 57.6 | 1.10 | 1.10 | 1.04 – 1.18 | 16.7 | 1.00 | 0.99 | 0.86 – 1.15 |
 | 35–39 | 58.8 | 1.12 | 1.15 | 1.08 – 1.22 | 17.0 | 1.01 | 0.96 | 0.82 – 1.13 |
 | 40–44 | 60.1 | 1.15 | 1.20 | 1.13 – 1.29 | 17.3 | 1.00 | 0.93 | 0.80 – 1.09 |
 | 45–49 | 61.2 | 1.17 | 1.23 | 1.15 – 1.32 | 16.1 | 0.90 | 0.83 | 0.70 – 0.98 |
 | 50–54 | 65.2 | 1.25 | 1.33 | 1.25 – 1.42 | 14.2 | 0.88 | 0.71 | 0.60 – 0.85 |
 | 55–59 | 67.6 | 1.29 | 1.39 | 1.30 – 1.48 | 13.0 | 0.74 | 0.64 | 0.54 – 0.77 |
 | 60–64 | 70.2 | 1.34 | 1.43 | 1.35 – 1.53 | 11.8 | 0.67 | 0.58 | 0.48 – 0.70 |
 | 65–69 | 76.8 | 1.47 | 1.57 | 1.47 – 1.67 | 9.4 | 0.58 | 0.47 | 0.38 – 0.58 |
 | 70–74 | 76.7 | 1.46 | 1.57 | 1.47 – 1.67 | 10.5 | 0.53 | 0.52 | 0.43 – 0.63 |
 | 75–79 | 73.6 | 1.41 | 1.52 | 1.43 – 1.63 | 11.2 | 0.51 | 0.55 | 0.44 – 0.67 |
 | 80+ | 72.8 | 1.39 | 1.50 | 1.40 – 1.61 | 10.4 | 0.57 | 0.49 | 0.39 – 0.62 |
Further education (years) | |||||||||
(N = 24364) | None | 66.3 | 13 | 13 | Â | 13.3 | 1 | 1 | Â |
 | Less than 2 | 64.5 | 0.94 | 1.01 | 0.97 – 1.05 | 14.8 | 1.12 | 1.05 | 0.92 – 1.19 |
 | 2–4 | 63.8 | 0.86 | 0.99 | 0.96 – 1.02 | 14.6 | 1.10 | 1.07 | 0.98 – 1.17 |
 | 5 or more | 62.2 | 0.73 | 0.96 | 0.93 – 1.00 | 14.7 | 1.10 | 1.11 | 0.99 – 1.25 |
 | Undergoing education or other |  |  |  |  |  |  |  |  |
 |  | 66.0 | 0.91 | 1.06 | 1.01 – 1.10 | 12.4 | 0.94 | 0.91 | 0.76 – 1.08 |
Frequency of attendance (times per year) | |||||||||
(N = 25533) | 0–1 | 60.7 | 1 | 1 |  | 16.4 | 1 | 1 |  |
 | 2–3 | 61.9 | 1.02 | 1.04 | 1.00 – 1.07 | 15.7 | 0.95 | 0.91 | 0.82 – 1.01 |
 | 4–5 | 64.6 | 1.06 | 1.08 | 1.04 – 1.11 | 14.1 | 0.86 | 0.79 | 0.71 – 0.88 |
 | 6–7 | 65.1 | 1.07 | 1.10 | 1.05 – 1.14 | 14.1 | 0.86 | 0.74 | 0.66 – 0.84 |
 | 8–9 | 67.5 | 1.11 | 1.14 | 1.09 – 1.19 | 13.0 | 0.79 | 0.67 | 0.58 – 0.77 |
 | 10+ | 68.2 | 1.12 | 1.18 | 1.14 – 1.23 | 11.4 | 0.69 | 0.53 | 0.46 – 0.61 |
Duration of listing (years) | |||||||||
(N = 16985) | Less than 1 | 63.2 | 1 | 1 | Â | 16.5 | 1 | 1 | Â |
 | 1–2 | 64.6 | 1.02 | 1.00 | 0.95 – 1.05 | 13.6 | 0.82 | 0.89 | 0.75 – 1.05 |
 | 3–7 | 64.6 | 1.02 | 0.98 | 0.94 – 1.02 | 13.7 | 0.83 | 0.92 | 0.80 – 1.07 |
 | 8–12 | 65.5 | 1.04 | 0.97 | 0.92 – 1.02 | 13.4 | 0.81 | 0.93 | 0.80 – 1.08 |
 | 13+ | 68.3 | 1.08 | 1.00 | 0.95 – 1.05 | 11.9 | 0.72 | 0.85 | 0.73 – 0.99 |
Self-rated health | |||||||||
(N = 25533) | Excellent | 67.6 | 1 | 1 | Â | 12.0 | 1 | 1 | Â |
 | Very good | 64.5 | 0.95 | 0.92 | 0.89 – 0.94 | 12.5 | 1.04 | 1.14 | 1.01 – 1.29 |
 | Good | 65.0 | 0.96 | 0.83 | 0.81 – 0.86 | 14.6 | 1.22 | 1.66 | 1.46 – 1.87 |
 | Fair | 61.4 | 0.91 | 0.74 | 0.72 – 0.77 | 17.2 | 1.44 | 2.29 | 2.01 – 2.62 |
 | Poor | 58.2 | 0.86 | 0.69 | 0.65 – 0.74 | 18.6 | 1.56 | 2.66 | 2.21 – 3.20 |
Chronic condition | |||||||||
(N = 25170) | No | 62.3 | 1 | 13 | Â | 14.8 | 1 | 1 | Â |
 | Yes-KRTC | 70.6 | 1.13 | 1.06 | 1.03 – 1.09 | 12.2 | 0.83 | 0.89 | 0.81 – 0.99 |
 | Yes-other or multiple | 63.9 | 1.03 | 1.04 | 1.01 – 1.06 | 14.7 | 0.99 | 0.89 | 0.82 – 0.96 |
Chronic condition | |||||||||
(N = 17192) | None | 62.3 | 1 | 13 | Â | 14.8 | 1 | 1 | Â |
 | K – Cardiovascular | 72.1 | 1.16 | 1.05 | 1.01 – 1.09 | 10.7 | 0.73 | 0.85 | 0.73 – 1.00 |
 | R – Respiratory | 66.5 | 1.07 | 1.06 | 1.01 – 1.11 | 14.9 | 1.01 | 0.99 | 0.85 – 1.15 |
 | T – Endocrine | 69.8 | 1.12 | 1.04 | 1.00 – 1.09 | 13.7 | 0.93 | 1.01 | 0.85 – 1.20 |
 | C – Cancer | 77.7 | 1.25 | 1.20 | 1.12 – 1.28 | 6.6 | 0.44 | 0.46 | 0.29 – 0.73 |